Panacea Life Sciences Holdings, Inc.
Cash Flow Statement
| Line Item | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-1.4M | $-2.2M | $-2.2M | $-1.9M | $-1.8M | $-1.7M | $-2.7M | $-2.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $383.5K | $443.6K | $424.0K | $422.7K | $422.6K | $429.4K | $421.7K | $409.9K |
| Amortization | — | — | — | — | — | $15.4K | $15.4K | $15.4K |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-357.1K | $1.6K | $-728.9K | $-483.3K | $-313.9K | $-523.0K | $-711.1K | $-729.5K |
| Investing Activities | ||||||||
| Capital Expenditures | $5.0K | — | — | $9.4K | $15.2K | $98.8K | $127.4K | $7.9K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-5.0K | $-17.9K | $-22.8K | $-9.4K | $-15.2K | $-98.8K | $-127.4K | $39.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $368.8K | $115.8K | $745.0K | $427.6K | $395.4K | $592.0K | $838.7K | $671.0K |
| Net Change in Cash | $6.7K | $99.4K | $-6.7K | $-65.0K | $66.3K | $-29.8K | $262 | $-19.5K |
| Free Cash Flow | $-362.1K | — | — | $-492.7K | $-329.1K | $-621.8K | $-838.4K | $-737.3K |